Wound healing and diabetes mellitus

Clinics in Plastic Surgery

Volumn 30, Issue 1, 2003, Pages 37-45

  Greenhalgh, David G ^a,b  

^a SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; ANTIBIOTIC AGENT; BECAPLERMIN; CIPROFLOXACIN; CLINDAMYCIN; KERATINOCYTE GROWTH FACTOR; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; RECOMBINANT GROWTH FACTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SOMATOMEDIN B; SOMATOMEDIN C; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; AMPUTATION; ATHEROSCLEROSIS; BIOENGINEERING; CELL TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEBRIDEMENT; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; FOOT ULCER; GENE THERAPY; HUMAN; HYPERBARIC OXYGEN; HYPERGLYCEMIA; PATHOPHYSIOLOGY; PLASTER CAST; PROTEIN EXPRESSION; REVIEW; SKIN GRAFT; TISSUE ENGINEERING; TISSUE REPAIR; UREMIA; VIRAL GENE DELIVERY SYSTEM; WOUND HEALING; WOUND INFECTION;

CHRONIC DISEASE; DIABETES MELLITUS; DIABETIC FOOT; HUMANS; WOUND HEALING;

EID: 0037218315     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-1298(02)00066-4     Document Type: Review

References (59)

1. Cunha BA. Antibiotic selection for diabetic foot infections: a review. J Foot Ankle Surg 2000;39:253-7.
2. Caputo GM, Cavanaugh PR, Ulbrecht JS, et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994;331:854-60.
3. Goodson WH, Hunt TK. Wound healing and the diabetic patient. Surg Gynecol Obstet 1979;149:600-8.
4. Boulton AJM, Vileikyte L. Pathogenesis of diabetic foot ulceration and measurements of neuropathy. Wounds 2000;12(Suppl):12B-8B.
5. Economides PA, Aristidis V. Etiopathogenesis of foot ulceration in diabetes. Wounds 2000;12(Suppl): 3B-6B.
6. Kamal K, Powell RJ, Sumpio BE. The pathobiology of diabetes mellitus: implications for surgeons. J Am Coll Surg 1996;183:271-89.
7. Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Diabetes 1987;36: 374-81.
8. Yue DK, McLennan S, Marsh M, et al. Effects of experimental diabetes, uremia, and malnutrition on wound healing. Diabetes 1987;36:295-9.
9. Frykberg RG, Mendeszoon ER. Charcot arthropathy: pathogenesis and management. Wounds 2000; 12(Suppl):35B-42B.
10. Brown RL, Breeden MP, Greenhalgh DG. PDGF and TGF-α act synergistically to improve healing in the genetically diabetic mouse. J Surg Res 1994;56:562-70.
11. Greenhalgh DG, Hummel III RP, Albertson A, Breeden MP. Synergistic actions of platelet-derived growth factor and the insulin-like growth factors in vivo. Wound Repair Reg 1993;1:69-81.
12. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Path 1990;136:1235-46.
13. Greenhalgh DG. The role of growth factors in wound healing. J Trauma 1996;41:159-67.
14. Brown DL, Kane CD, Chernausek SD, Greenhalgh DG. Differential expression and localization of IGF-I and IGF-II in cutaneous wounds of diabetic versus nondiabetic mice. Am J Pathol 1997;151:715-24.
15. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1995;270:12607-13.
16. Werner S, Breeden M, Greenhalgh DG, et al. Induction of keratinocyte growth factor is reduced and delayed during wound healing in the genetically diabetic mouse. J Invest Dermatol 1994;103:469-72.
17. Trengove NJ, Stacey MC, MacAuley S, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Reg 1999;7:442-52.
18. Neely AN, Clendening CE, Gardner J, Greenhalgh DG. Gelatinase activities in wounds of healing-impaired mice versus non-healing-impaired mice. J Burn Care Rehabil 2000;21:395-402.
19. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987;316:599-606.
20. Winegrad AI. Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987; 36:396-406.
21. Tesfamariam B, Cohen R. Role of sorbitol and myoinositol in the endothelial cells dysfunction caused by elevated glucose [abstract]. Fed Proc 1990;4:A867.
22. Lee TS, Saltman KA, Ohashi H, King G. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in diabetic vascular complications. Proc Natl Acad Sci USA 1989;86:5141-5.
23. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-21.
24. Yan S-D, Schmidt A-M, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycosylation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-97.
25. Kirsten M, Brett J, Radoff S, et al. Advanced glycosylation induces the transendothelial human monocyte chemotaxis and secretion of PDGF: role in vascular disease in diabetes and aging. Proc Natl Acad Sci USA 1990;87:9010-4.
26. Vlassara H, Brownlee M, Manogue KR, et al. Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodeling. Science 1988; 240:1546-8.
27. Kent MJC, Light ND, Bailey AJ. Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation. Biochem J 1985;225:745-52.
28. Lubec G, Pollak A. Reduced susceptibility of non-enzymatically glycosylated glomerular basement membrane to protease: is thickening of glomerular membrane due to reduced proteolytic degradation? Renal Physiol 1980;3:4-8.
29. Hammes H-P, Martin S, Federlin K, et al. Aminoguanidine treatment for the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991;88: 11555-8.
30. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes 1991; 40:1328-34.
31. Oyibo SO, Jude EB, Tarawneh I, et al. The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 2001;18:133-8.
32. Edelman D, Hough DM, Glazebrook KN, Oddone EZ. Prognostic value of the clinical examination of the diabetic foot ulcer. J Gen Intern Med 1997;12:537-43.
33. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999;22:692-5.
34. Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol 2000;136: 1531-5.
35. Diamantopoulos EJ, Haritos D, Yfandi G, et al. Management and outcome of severe diabetic foot infections. Exp Clin Endocrinol Diabetes 1998;106:346-52.
36. Kalani M, Brismar K, Fagrell B, et al. Transcutaneous oxygen tension and toe blood pressures as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999;22:147-51.
37. Rosenblum BI. Identifying the patient at risk of foot ulceration. Wounds 2000; 12(Suppl):7B-11B.
38. Armstrong DG, Lavery LA, Harkless LB. Options for off-loading the diabetic foot. Wounds 2000; 12(Suppl): 30B-4B.
39. Armstrong DG, Nguyen HC, Lavery LA, et al. Off-loading the diabetic foot: a randomized clinical trial. Diabetes Care 2001;24:1019-22.
40. Steed DL, Donohoe D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 1996;183: 61-4.
41. Bakker DJ. Hyperbaric oxygen therapy and the diabetic foot. Diabetes Metab Res Rev 2000;16(Suppl): S55-8.
42. Wunderlich RP, Lavery PEJ. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care 2000;23:1551-5.
43. Knighton DR, Fiegel VD, Austin LL, et al. Classification and treatment of chronic nonhealing wounds: successful treatment with autologous platelet -derived wound healing factors (PSWHF). Ann Surg 1986; 204:322-30.
44. Margolis DJ, Kantor J, Santanna J, et al. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001;24:483-4.
45. Blight A, Fatah MF, Datubo-Brown DD, et al. The treatment of door sites with cultured epithelial grafts. Br J Plast Surg 1991;44:12-9.
46. DeLuca M, Albanese E, Bondanza S, et al. Multicentre experience in the treatment of burns with autologous and allogenic cultured epithelium, fresh or preserved in a frozen state. Burns 1989;15:303-7.
47. Phillips TJ, Gilchrest BA. Cultured epidermal allografts as biologic wound dressings. Prog Clin Biol Res 1991;365:77-88.
48. Mansbridge J, Liu K, Patch R, et al. Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. Tissue Eng 1998;4:403-14.
49. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19:350-4.
50. Goretsky MJ, Harriger MD, Supp AP, et al. Expression of IL-α, IL-6, and bFGF by cultured skin substitutes before and after full-thickness wounds in athymic mice. J Trauma 1996;40:894-900.
51. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective, randomized multicenter clinical trial. Diabetes Care 2001;24:290-5.
52. d'Hemecourt P, Smiell J, Karim M. Sodium carboxymethylcellulose aqueous-based gel versus becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds 1998;10:69-75.
53. Embil JM, Papp K, Sibbald G, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen 2000;8:162-8.
54. Smiell J, Wieman T, Steed D, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor BB) in patients with nonhealing lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999;7: 335-46.
55. Steed DL. The Diabetic Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995;21:71-81.
56. Wieman J, Smiell J, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998;21:822-7.
57. Zagari M, Martens L, Gagnon D, Wieman T. Treatment of diabetic foot ulcers with topical recombinant growth factor gel achieves higher healing rates and results in lower projected costs of care [abstract]. Clinical Symposium on Wound Care, 1998.
58. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000;8: 480-93.
59. Pham HT, Rosenblum BI, Lyons TE, et al. Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective, randomized, clinical trial. Wounds 1996;11:79-86.